FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective NaV1.8 pain signal inhibitor for administration twice daily.
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback